Could controversies in the arena of fatty liver disease be a potential gate for the democratization of science?

Abstract

The term “democratization of science” describes the process of more evenly allocating epistemic authority between scientists, members of dominant civilizations, and the academic community at large, or members of less dominant societies. This means that it includes initiatives aimed at democratizing the decision-making process by acknowledging the presence of diverse types of “wisdom of crowd” and so reducing the barriers between the various stakeholders. Our purpose is to separate influence from involvement that contributes to the breakdown of conventional closed-circuit authority structures and to prevent future abuses of power by academic institutions, scientific societies, and even individual opinion leaders. A conceptual framework for comprehending the idea of the democratization of science is presented in this perspective piece. Our considerations are pertinent to the politics of widespread academic engagement in scientific decision-making, even though they were spurred by the discussion surrounding the definitions of fatty liver disease.

Keywords

MAFLD / NAFLD / fatty liver / democratization / science

References

[1] Fouad Y,Zheng MH.The NAFLD-MAFLD debate: is there a consensus-on-consensus methodology?.Liver Int2022;42:742-8

[2] Fouad Y,Elsahhar M.The NAFLD-MAFLD debate: eminence vs evidence.Liver Int2021;41:255-60

[3] Méndez-Sánchez N,Kawaguchi T.Editorial: the metabolic (dysfunction) associated fatty liver disease (MAFLD)-non-alcoholic fatty liver disease (NAFLD) debate: a forced consensus and the risk of a world divide.Med Sci Monit2022;28:e938080 PMCID:PMC9389952

[4] Fouad YM,El Etreby RM,Attia D.Editorial: the metabolic (dysfunction)-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) debate: why the american association for the study of liver diseases (AASLD) and European association for the study of the liver (EASL) consensus process is not representative.Med Sci Monit2022;28:e938066 PMCID:PMC9462522

[5] Malhi H,Lim JK.Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals.Liver Transpl2023;29:1262-3

[6] Shiha G,Eskridge W.Redefining fatty liver disease: an international patient perspective.Lancet Gastroenterol Hepatol2021;6:73-9

[7] Sanal MG.Is the change from NAFLD to MASLD driven by political correctness?.J Hepatol2024;80:e74-6

[8] Alboraie M,Eslam M.Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective?.Hepatology2024;Online ahead of print:

[9] Eslam M,Vajro P.Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.Lancet Gastroenterol Hepatol2021;6:864-73

[10] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[11] Eslam M,George J.International Consensus PanelMAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[12] Eslam M,Wong VW.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int2020;14:889-919

[13] Eslam M,Francque S.Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nat Rev Gastroenterol Hepatol2022;19:638-51

[14] Kurtulmuş F. The democratization of science. Global Epistemologies and Philosophies of Science. London: Routledge; 2021. pp. 145-54.

[15] Carolan MS.Science, expertise, and the democratization of the decision-making process.Soc Natur Resour2006;19:661-8

[16] Méndez-Sánchez N,Gish RG.Global multi-stakeholder consensus on the redefinition of fatty liver diseaseGlobal multi-stakeholder endorsement of the MAFLD definition.Lancet Gastroenterol Hepatol2022;7:388-90

[17] Méndez-Sánchez N,Alonso-Rivera CG.Latin American association of pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.J Hepatol2022;77:249

[18] Nan Y,Bao J.The Chinese society of hepatology position statement on the redefinition of fatty liver disease.J Hepatol2021;75:454-61

[19] Shiha G,Al Khatry M.Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.Lancet Gastroenterol Hepatol2021;6:57-64

[20] Spearman CW,Ocama P.The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.J Hepatol2021;74:1256-8

[21] Berlivet L.Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science.Med Anthropol Q2020;34:525-41 PMCID:PMC7753536

[22] Moss SF. The great ulcer war: how it all happened. Available from: https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2815%2900584-3 [Last accessed on 29 May 2024]

[23] Beuers U,Gish RG.Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'.Gut2015;64:1671-2

[24] Angeli P.Democracy in science.J Hepatol2024;80:676-7

[25] Lonardo A,Caldwell SH.Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature.J Hepatol2024;80:e192-4